Medicare's decision to limit coverage for a controversial new Alzheimer's drug has prompted an outcry among Alzheimer's advocates. The drug is Aduhelm, and despite widespread enthusiasm for it among Alzheimer's patients and advocates, it hasn't been proven to slow the disease. The drug was given accelerated approval by the Food and Drug Administration because it reduces the plaque that develops in the brains of most Alzheimer’s patients.
NCCN Policy Summit Explores the Promise and Challenges of New Technologies in Cancer Care prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.